Payment overview · 2025
General Payments
$1,505.23
47 reported records · 13 companies
Healthcare provider profile · identity verified
Kaitlyn Riley
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · FAIRFIELD, CA · NPI 1659945749
Verified facts
What the public records show
CMS Open Payments records show Kaitlyn Riley received $1,505.23 in general payments during 2025 across 47 reported records.
Gilead Sciences, Inc. accounted for 20.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $304.83 | 20.2% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $275.96 | 18.3% | 9 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $257.32 | 17.1% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $179.76 | 11.9% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $153.98 | 10.2% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $90.45 | 6.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $78.66 | 5.2% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $52.07 | 3.5% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $34.74 | 2.3% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $28.36 | 1.9% | 1 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $17.45 | 1.2% | 1 | 2025 |
| ALK-Abello, Inc | Unresolved — no canonical attribution shown | $16.44 | 1.1% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $15.21 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,493.67 | 46 |
| Education | $11.56 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $206.66 | 5 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $192.52 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $179.76 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $142.42 | 2 | 2025 |
Source payment records
|
|||||
| Epclusa Normalized: epclusa |
Drug | Gilead Sciences, Inc. | $121.83 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $90.45 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $64.38 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $64.38 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $55.63 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $52.07 | 3 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $47.41 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $38.69 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $34.74 | 2 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $28.36 | 1 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| RUKOBIA Normalized: rukobia |
Drug | ViiV Healthcare Company | $17.39 | 1 | 2025 |
Source payment records
|
|||||
| Grastek Normalized: grastek |
Drug | ALK-Abello, Inc | $16.44 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ALK-Abello, Inc | $16.44 | 1 | 2025 |
Source payment records
|
|||||
| Odactra Normalized: odactra |
Drug | ALK-Abello, Inc | $16.44 | 1 | 2025 |
Source payment records
|
|||||
| Ragwitek Normalized: ragwitek |
Drug | ALK-Abello, Inc | $16.44 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $14.28 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $11.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 58 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
80 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
60 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
59 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 650 | 178 |
| Metformin Hcl | Metformin Hcl | 340 | 106 |
| Lisinopril | Lisinopril | 319 | 97 |
| Amlodipine Besylate | Amlodipine Besylate | 283 | 85 |
| Losartan Potassium | Losartan Potassium | 219 | 71 |
| Hydrochlorothiazide | Hydrochlorothiazide | 213 | 62 |
| Levothyroxine Sodium | Levothyroxine Sodium | 178 | 46 |
| Gabapentin | Gabapentin | 158 | 46 |
| Simvastatin | Simvastatin | 123 | 39 |
| Omeprazole | Omeprazole | 113 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 105 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 101 | 54 |
| Alendronate Sodium | Alendronate Sodium | 86 | 25 |
| Furosemide | Furosemide | 83 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 81 | 33 |
| Ibuprofen | Ibuprofen | 80 | 25 |
| Jardiance | Empagliflozin | 80 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 74 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 70 | 23 |
| Montelukast Sodium | Montelukast Sodium | 66 | 20 |
| Allopurinol | Allopurinol | 63 | 23 |
| Trulicity | Dulaglutide | 60 | 13 |
| Rybelsus | Semaglutide | 59 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 58 | 17 |
| Ozempic | Semaglutide | 58 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 56 | 18 |
| Trazodone Hcl | Trazodone Hcl | 54 | 12 |
| Glipizide | Glipizide | 49 | 16 |
| Carvedilol | Carvedilol | 47 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | 15 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 45 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 15 |
| Mirtazapine | Mirtazapine | 43 | suppressed |
| Naproxen | Naproxen | 43 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 42 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 40 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 39 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 32 | 11 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 32 | suppressed |
| Meloxicam | Meloxicam | 30 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 29 | suppressed |
| Famotidine | Famotidine | 28 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 28 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Carbamazepine Er | Carbamazepine | 24 | suppressed |
| Lacosamide | Lacosamide | 24 | suppressed |
| Potassium Chloride | Potassium Chloride | 24 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Carbamazepine | Carbamazepine | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 19 | suppressed |
| Clotrimazole | Clotrimazole | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 16 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | 11 |
| Lurasidone Hcl | Lurasidone Hcl | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,505.23 · 47 records | Gilead Sciences, Inc. | AFREZZA, AIRSUPRA, APRETUDE, BREZTRI, Cologuard Collection Kit, DOVATO, Epclusa, Grastek, Kerendia, MAVYRET, MOUNJARO, NEFFY, Odactra, Ozempic, PIFELTRO, QULIPTA, RUKOBIA, Ragwitek, UBRELVY, Veozah, Wegovy, ZEPBOUND, ZTLido | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error